Illumina (ILMN)
(Delayed Data from NSDQ)
$100.11 USD
+0.14 (0.14%)
Updated Oct 24, 2025 04:00 PM ET
After-Market: $100.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ILMN 100.11 +0.14(0.14%)
Will ILMN be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ILMN based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for ILMN
Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last?
ILMN: What are Zacks experts saying now?
Zacks Private Portfolio Services
PacBio Aims to Expand Multiomic Capabilities Via Latest Innovations
KMDA or ILMN: Which Is the Better Value Stock Right Now?
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Other News for ILMN
Earnings week ahead: AAPL, MSFT, AMZN, META, GOOG, BA, XOM, CVX, PFE, MA, V, PYPL, SOFI, and more
Is ILMN poised for gains? MACD Bullish Centerline Cross shows up after gaining 0.14%
ILMN Crossed Above 50 Day Moving Average on October 23
Illumina price target lowered to $105 from $106 at Baird
Illumina price target lowered by $1 at Baird, here's why